# Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

> **NCT03334786** · PHASE1,PHASE2 · TERMINATED · sponsor: **Flex Pharma, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Fasciculation

## Interventions

- **DRUG:** FLX-787-ODT

## Key facts

- **NCT ID:** NCT03334786
- **Lead sponsor:** Flex Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-05
- **Primary completion:** 2018-08-23
- **Final completion:** 2018-08-23
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Development of Current Formulation has Ceased
- **Last updated:** 2018-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03334786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03334786, "Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03334786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*